Literature DB >> 27013092

Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on IPF induced by Bleomycin in rats and regulation of TGF-β1/Smad3.

Fei Chen1, Peng-Li Wang1, Xin-Sheng Fan2, Jing-Hua Yu3, Yue Zhu4, Zhen-Hua Zhu4.   

Abstract

AIM OF THE STUDY: Idiopathic pulmonary fibrosis (IPF), one of the clinical common diseases, shares similar pathogenesis with ancient disease "Feibi" in Chinese medicine, Renshen pingfei decoction (RPFS), a classical prescription, was commonly used in treating Feibi. In the current study, the protective role of RPFS in rats model of IPF and the mechanism via regulation of TGF-β1/Smad3, were evaluated and explored.
METHODS: The chemicals of RPFS were analyzed by UPLC-QTOF-MS. Under the optimized chromatographic and MS condition, the major components in RPFS were well separated and detected. An IPF model was established in rats which were induced with Bleomycin (BLM). After treated with corresponding medicine for 7 days, 14 days, 21 days and 28 days respectively, lung function of rats were measured; peripheral blood and bronchoalveolar lavage fluid (BALF) were assessed; histopathological changes and homogenate of lung tissue were detected; TGF-β1 and Smad3 mRNA and protein expressions in lung tissue were examined as well.
RESULTS: 43 signal peaks of chemical components in RPFS were identified by UPLC-QTOF-MS method. Compared with model group, RPFS group exerted significant effects on IPF model rats in improving lung function and decreasing HYP content of lung tissue (P<0.01), reducing the level of TGF-β1 and NFκB in BALF (P<0.05), decreasing SOD and MDA level in serum (P<0.01), as well as down-regulating TGF-β1 and Smad3 mRNA and protein expressions of lung tissue (P<0.01).
CONCLUSION: RPFS could reduce the lung injury and fibrosis degree and improve lung function of IPF model rats. The protective role might mediated by down-regulating TGF-β1/Smad3 signaling pathway.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Idiopathic pulmonary fibrosis; NFκB; Panax ginseng C.A.Mey.; Renshen Pingfei Decoction; TGF-β1/Smad3

Mesh:

Substances:

Year:  2016        PMID: 27013092     DOI: 10.1016/j.jep.2016.03.051

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  10 in total

Review 1.  Panax ginseng C. A. Meyer as a potential therapeutic agent for organ fibrosis disease.

Authors:  Hao Liu; Chongning Lv; Jincai Lu
Journal:  Chin Med       Date:  2020-11-24       Impact factor: 5.455

2.  Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis.

Authors:  Yufeng Zhang; Lina Gu; Qingqing Xia; Lijun Tian; Jia Qi; Mengshu Cao
Journal:  Front Pharmacol       Date:  2020-04-30       Impact factor: 5.810

3.  Efficacy of TCM therapy of tonifying lung-kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis: A case report.

Authors:  Ming-Jun Chen; Ge-Lliang Yang; Yu-Xuan Ding; Zhan-Qi Tong
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 4.  Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects.

Authors:  Liu-Cheng Li; Lian-Di Kan
Journal:  J Ethnopharmacol       Date:  2016-12-28       Impact factor: 4.360

Review 5.  Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis.

Authors:  Mahbub Hasan; Nidhan Chandra Paul; Shamrat Kumar Paul; Abu Saim Mohammad Saikat; Hafeza Akter; Manoj Mandal; Sang-Suk Lee
Journal:  Molecules       Date:  2022-02-22       Impact factor: 4.411

6.  Role of nuclear factor-kappa B in bleomycin induced pulmonary fibrosis and the probable alleviating role of ginsenoside: histological, immunohistochemical, and biochemical study.

Authors:  Dalia Refaat El-Bassouny; Nesreen Mostafa Omar; Hanaa Attia Khalaf; Reem Ahmad Abd Al-Salam
Journal:  Anat Cell Biol       Date:  2021-12-31

7.  Long-Term Effects of TCM Yangqing Kangxian Formula on Bleomycin-Induced Pulmonary Fibrosis in Rats via Regulating Nuclear Factor-κB Signaling.

Authors:  Meng Li; Ya Li; JianSheng Li; Peng Zhao; Yunping Bai; SuXiang Feng; Xuefang Liu; Yang Wang; Qingqing Bian; Junzi Li
Journal:  Evid Based Complement Alternat Med       Date:  2017-12-07       Impact factor: 2.629

Review 8.  Drugs and Targets in Fibrosis.

Authors:  Xiaoyi Li; Lixin Zhu; Beibei Wang; Meifei Yuan; Ruixin Zhu
Journal:  Front Pharmacol       Date:  2017-11-23       Impact factor: 5.810

9.  The Influence of BuqiHuoxueTongluo Formula on Histopathology and Pulmonary Function Test in Bleomycin-Induced Idiopathic Pulmonary Fibrosis in Rats.

Authors:  Xiaolin Yu; Yanxia Zhang; Xiaohua Yang; Xiaomei Zhang; Xinxiang Wang; Xuemei Liu; Yan Yan
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629

Review 10.  The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs.

Authors:  Hao Shen; Nu Zhang; Yuqing Liu; Xuerong Yang; Yuanyuan He; Qi Li; Xiaoyan Shen; Yulian Zhu; Yong Yang
Journal:  Front Pharmacol       Date:  2022-01-05       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.